Press Enter to search · Esc to close
Endocrinologists are quietly rewriting the rulebook — treating diabetes, fatty liver, and heart disease as one slow-burning inflammatory story. Here's what that means for the rest of us.
A new NHANES analysis suggests a simple index pulled from a routine CBC — the Systemic Immune-Inflammatory Index — tracks with mortality risk in metabolic syndrome. Here's what it is, and what it isn't.
Two new population studies suggest the cholesterol number on your lab slip may be quietly underselling your real cardiovascular risk — especially if you're carrying belly weight or creeping insulin resistance.
A 40,000-person Chinese cohort found that a number you can calculate from a routine lipid panel tracks with incident aortic valve calcification — and inflammation explains part of the link.
A 2026 meta-analysis pools a decade of evidence on how common metabolic syndrome has become — and how much of it tracks back to the lifestyle levers we actually control.
A common gut bacterium called Blautia wexlerae appears to rewrite dietary fats into signals that nudge GLP-1 release. The science is early — but the mechanism is genuinely new.
A new federal survey puts a real number on how many Americans with diabetes are now on GLP-1 shots — and it's reshaping what we should expect from the next wave of metabolic drugs.
A new legal analysis warns that the same patent playbook that kept inhalers expensive for decades is now being run on GLP-1 drugs — just as millions of women are lining up for them.
The shots that started as diabetes medicine and became weight-loss icons are quietly rewriting their own job description. The 2025 evidence points to a multi-organ story — with caveats worth knowing.
The shots that started as diabetes drugs and exploded as weight-loss icons are turning out to do a lot more than mute hunger. New research traces their fingerprints across the hindbrain, the kidney's salt switches, and the hormone that tells you it's lunchtime.